Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care.
HER2-directed therapy
breast cancer
community
research
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
24 Jun 2020
24 Jun 2020
Historique:
received:
06
05
2020
revised:
10
06
2020
accepted:
18
06
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
epublish
Résumé
The development of new HER2-directed therapies has resulted in a significant prolongation of survival for women with metastatic HER2-positive breast cancer. Discoveries in the laboratory inform clinical trials which are the basis for improving the standard of care and are also the backbone for quality improvement. Clinical trials can be completed more rapidly by expanding trial enrollment to community sites. In this article we review some of the challenges in treating metastatic breast cancer with HER2-directed therapies and our strategies for incorporating our community partners into the research network.
Identifiants
pubmed: 32599960
pii: jcm9061984
doi: 10.3390/jcm9061984
pmc: PMC7355741
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : K12 CA001727
Pays : United States
Références
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
J Clin Oncol. 2009 Jan 1;27(1):2-5
pubmed: 19047306
Future Oncol. 2020 Mar;16(7):247-254
pubmed: 32057254
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
Clin Cancer Res. 2017 Oct 1;23(19):5687-5695
pubmed: 28679771
J Clin Oncol. 2020 Feb 10;38(5):444-453
pubmed: 31821109
Anticancer Res. 2014 Apr;34(4):1483-91
pubmed: 24692675
J Clin Oncol. 1999 Sep;17(9):2639-48
pubmed: 10561337
J Clin Oncol. 2010 Mar 1;28(7):1138-44
pubmed: 20124182
J Nucl Med. 2019 Jan;60(1):23-25
pubmed: 30573641
J Clin Oncol. 2012 Jul 20;30(21):2585-92
pubmed: 22689807
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
J Clin Oncol. 2004 Mar 15;22(6):1063-70
pubmed: 15020607
J Natl Compr Canc Netw. 2015 Sep;13(9):1061-4
pubmed: 26358790
J Natl Cancer Inst. 1993 Aug 4;85(15):1230-5
pubmed: 8101229
Oncotarget. 2017 Sep 4;8(43):73362-73363
pubmed: 29088709
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
Cancer Discov. 2013 Feb;3(2):224-37
pubmed: 23220880
J Natl Cancer Inst. 2013 Dec 4;105(23):1782-8
pubmed: 24262440
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Gynecol Obstet Invest. 2020;85(3):259-266
pubmed: 32289805
J Clin Oncol. 2018 Sep 10;36(26):2736-2740
pubmed: 29939838
J Clin Oncol. 2020 May 29;:JCO2000775
pubmed: 32468955
Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):1-7
pubmed: 18685491
Hong Kong Med J. 2008 Apr;14(2):130-5
pubmed: 18382020
Oncotarget. 2017 Nov 1;8(60):102458-102467
pubmed: 29254261
Cancer Res. 1993 Oct 15;53(20):4960-70
pubmed: 8104689
N Engl J Med. 2019 Sep 26;381(13):1284-1286
pubmed: 31502769
J Nucl Med. 2014 Jan;55(1):23-9
pubmed: 24337604
Cancer. 2015 Nov 1;121(21):3885-93
pubmed: 26218755
Breast. 2015 Nov;24 Suppl 2:S26-35
pubmed: 26253814
N Engl J Med. 2006 Dec 28;355(26):2733-43
pubmed: 17192538
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
N Engl J Med. 2020 Feb 13;382(7):597-609
pubmed: 31825569
J Clin Oncol. 2011 Feb 1;29(4):398-405
pubmed: 21172893
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153